Response to comment on: Löndahl et al. Hyperbaric Oxygen Therapy Facilitates Healing of Chronic Foot Ulcers in Patients With Diabetes. Diabetes Care 2010;33:998–1003 by Löndahl, Magnus et al.
COMMENTS AND
RESPONSES
Responsetocomment
on: Löndahl et al.
Hyperbaric Oxygen
Therapy Facilitates
Healing of Chronic
Foot Ulcers in
Patients With
Diabetes. Diabetes
Care 2010;33:
998–1003
T
here is increasing evidence for the
use of hyperbaric oxygen therapy
(HBOT) in selected patients with
chronic diabetic foot ulcers (1). However,
several issues still need to be answered,
including health economics.
In an editorial commenting on our
study, Lipsky and Berendt (2) reported
costs between $50,000 and $200,000
for a full course of HBOT treatment in
the U.S. Van der Staal et al. (3) report
signiﬁcantly lower cost/reimbursement
in the Netherlands at €6,916 for 40
HBOT sessions. Our Hyperbaric Centre
in the southern part of Sweden is reim-
bursed €9,462 for 40 HBOT sessions,
whereas at another Swedish center, the
same treatment schedule is reimbursed
with €21,505. It must further be stated
that these European ﬁgures only include
HBOT. Accompanying expenses such as
traveling andhotelcostsare notincluded.
In summary, the cost of a full course
HBOT treatment for diabetic foot ulcer
variesconsiderablyfromonecentertoan-
other and might depend on set-up costs,
ongoing costs, reimbursement systems,
andnumberofpatientstreatedpercenter.
Of more importance than the actual
cost is the full health economical evalua-
tion of a treatment. Some health economic
analyses evaluating the cost-effectiveness
of HBOT in diabetic foot ulcer treatment
havebeenpublished, buttheyarelimited
by deﬁcient primary clinical data and
should be interpreted with caution (4–6).
Still, these studies suggest a potential cost-
effectivenessofHBOT,i.e.,acrudeanalysis
of the small but high-quality double-blind
randomized clinical trial by Abidia et al.
(5),only taking HBOT and dressing costs
into account, suggests a saving of £2,960
per patient during the 1st year of follow-
up (4).
However, the cost-effectiveness of
HBOT could not be considered as estab-
lished as long as robust health economic
data—basedonevaluationoflargeplacebo-
controlled randomized clinical trials eval-
uating the effect of HBOT as adjunctive
treatment in a selected and speciﬁed pop-
ulation of patients with chronic diabetic
foot ulcers—is lacking. The health eco-
nomic analysis of HBOT in the setting of
the Hyperbaric Oxygen Therapy in Dia-
beticswithChronicFootUlcers(HODFU)
study is ongoing, hopefully making some
more information available.
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